Please assess the completion status of the following clinical trial:

Trial Title: Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Documented chronic genotype 1 or genotype 4 HCV infection~* Naïve to all HCV antiviral treatment(s)~* Agree to IL28B genotyping~* A body mass index \>18 kg/m2 but not exceeding 36 kg/m2~* Liver biopsy obtained within 3 years (36 calendar months) prior to the Day 1 visit, with a fibrosis classification of non-cirrhotic. If no recent (\<36 months) liver biopsy is available, a study qualifying biopsy must be performed prior to Baseline (Day 1)~* All fertile males and females must use two forms of effective contraception between them during treatment and during the 24 weeks after treatment ends~* Otherwise healthy as determined by the medical history, physical examination, ECG findings, and clinical laboratory measurements performed at Screening~Key Exclusion Criteria:~* Positive test at Screening for hepatitis B surface antigen (HBsAg) or anti-human immunodeficiency virus antibody~* History of any other clinically significant chronic liver disease~* History of ascites, variceal hemorrhage, hepatic encephalopathy, or conditions consistent with decompensated liver disease~* Positive results on urine screen for drugs of abuse test at Screening (unless used as medical treatment, e.g., with a prescription)~* History of alcohol/drug abuse or dependence within 6 months of the study start (unless participating in a controlled rehabilitation program)~* Screening ECG corrected QT interval value greater than 450 ms and/or clinically significant ECG findings~* A personal or family history of Torsade de Pointes findings~* Pregnant or nursing women~* Males with a female partner who is pregnant~* Abnormal hematological and biochemical parameters as specified in the protocol~* History of major organ transplantation with an existing functional graft~* Thyroid dysfunction not adequately controlled~* Subjects with a history of suicide attempt or hospitalization for depression in the past 5 years and/or any current (within 6 months) severe or poorly controlled psychiatric disorder~* History or current evidence of immunologic disorder; pulmonary, cardiac, or pulmonary disease; seizure disorder; cancer or history of malignancy that in the opinion of the investigator makes the subject unsuitable for the study~* Participation in a clinical study with an investigational drug, biologic, or device within 3 months prior to first dose administration

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- GSK2336805 (Type: EXPERIMENTAL): Study Part 1
- Placebo (Type: PLACEBO_COMPARATOR): Study Part 1
- GSK2336805 + pegylated interferon alfa-2a + ribavrin (Type: EXPERIMENTAL): Study Part 2
- Placebo + pegylated interferon alfa-2a + ribavirin (Type: ACTIVE_COMPARATOR): Study Part 2

Based on this trial design, predict the completion outcome and termination type (if applicable).